Nuropod has announced a professional partnership program for practitioners and clinics, offering access to CPD-accredited AVNT™ education through the Parasym Scientific Network, device trial opportunities, and direct contact with the research team.

Sacramento, United States, November 2, 2026 /PressCable/ -- Nuropod has opened its professional partnership program to practitioners and clinics across the United States, providing access to its wearable vagus nerve stimulation technology, CPD-accredited training, onboarding support, and clinical implementation guidance.

More information is available at https://nuropod.com/pages/for-professionals

The announcement comes as more practices look for non-invasive services they can offer in the clinic and that clients can continue between appointments at home. Nuropod’s program aims to address this demand, pairing direct access to Parasym’s science and research team with a device backed by more than 60 completed clinical studies, including randomized, placebo-controlled research.

For individual practitioners, the program operates through Nuropod’s Healthcare Professional Program, which invites members to join the Parasym Scientific Network. Participants can learn about the studies, science, and recommended protocols behind Parasym’s proprietary AVNT™ waveform and become AVNT practitioners through CPD-accredited education. The program also offers opportunities to trial the device with users and direct access to the scientific research team. Practitioners apply through an online form on the professionals page.

For clinics and medical spas, the program introduces non-invasive vagal neuromodulation alongside existing services. Sessions can run without consumables, and clients can continue at home between appointments through designated continuation protocols, which the company says supports client retention. Partner practices also receive dedicated professional pricing.

A separate Parasym Research Network serves researchers. Members gain access to publications and peer-reviewed studies, can collaborate on research opportunities in shared fields of interest, and can inquire directly about potential research partnerships. Athletes and performance professionals are directed to a dedicated performance site.

Nuropod is trusted by more than 1,000 healthcare professionals and has recorded over 5 million user sessions. Its underlying technology reflects more than 10 years of research and development, with over 100 clinical studies currently underway.

Practitioners and clinics can apply or request partnership details at https://nuropod.com/

Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-significant risk device and is not intended to diagnose, treat, cure, or prevent any disease.

Contact Info:
Name: PR Team
Email: Send Email
Organization: Nuropod by Parasym
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/

Source: PressCable

Release ID: 89208237

Should any errors, concerns, or inconsistencies arise from the content provided in this press release that require attention or if a press release needs to be taken down, we kindly request that you immediately contact us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for timely assistance within 8 hours – taking necessary measures to rectify identified issues or providing guidance on the removal process. We prioritize delivering accurate and reliable information.